Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Strain Specificity

Why "Probiotics" Is the Wrong Question

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

228 human trials, about 1000 studies, Synthesized across hundreds of trials. The written rationale for this grade is still being prepared.

FDA
A scientific principle, not a product
WADA
Not applicable

Reference only. Not medical advice.

What can go wrong

The principle itself carries no risk; ignoring it does. Buying a probiotic because the genus or species matches a studied one, while the actual strain does not, wastes money on a product with no evidence for the intended use, and assuming a strain proven for one condition works for another is a common, evidence-free leap. Because probiotics are used in vulnerable settings, including pregnancy, infancy, and immune-compromised or critically ill people, strain and dose selection should be discussed with a qualified healthcare provider rather than chosen from label marketing alone.

The single most load-bearing principle in probiotic science is that benefits are strain-specific and disease-specific, not a general property of the word 'probiotic.' A probiotic is defined by genus, species, and strain, for example Lactobacillus rhamnosus GG, and evidence for one strain in one condition does not transfer to a different strain of the same species or to a different condition. A systematic review of 228 randomized trials found this directly: L. rhamnosus GG was effective for pediatric antibiotic-associated diarrhea but not for six other conditions, and two L. casei strains gave very different results for the same indication. The practical consequence is that a genus or species name alone, the most common thing on a label, tells you almost nothing about whether a product has evidence for its claimed use.

The most important and most ignored fact in probiotics: effects are strain-specific and disease-specific, not a general "probiotic" property.

What it is invoked to explain

Claims this idea is used to support. Whether it supports them is the rest of the entry.

  • Evaluating whether a product's exact strains match its specific claims
  • Understanding why most broad probiotic marketing is unsupported
  • Matching specific strains to specific conditions rather than by genus
  • Reading probiotic labels for the full genus-species-strain designation
  • Judging whether a meta-analysis validly pooled the same strain or mixed unrelated ones
  • Explaining why a well-studied strain can still be the wrong choice for a given use

What people get wrong

  • Often saidIf a study shows 'Lactobacillus' works, any Lactobacillus product works

    ActuallyEffects are strain-specific. In McFarland's 228-trial review, two Lactobacillus casei strains gave 6.7 versus 33.3 percent results for the same indication. A benefit shown for one strain does not transfer to another strain of the same species, let alone a different species. The exact strain designation is what carries the evidence.

  • Often saidProbiotics are good for 'gut health' in general

    ActuallyThere is no general 'probiotic' effect. Evidence is associated with specific strains in specific conditions, for example S. boulardii CNCM I-745 for antibiotic-associated diarrhea. The same review found L. rhamnosus GG helped pediatric antibiotic diarrhea but showed no benefit across six other conditions, so whole-category 'gut health' claims are largely unsupported.

  • Often saidThe genus and species on the label are enough to match a product to research

    ActuallyThey are not. ISAPP consumer guidance notes that a large share of retail supplements omit strain designations, and only about a third of surveyed products could be linked by strain and dose to actual health-benefit evidence. Without the strain, a label cannot be tied to a study.

  • Often saidA strain proven for one condition works for related conditions too

    ActuallyEfficacy is disease-specific as well as strain-specific. S. boulardii CNCM I-745 has trial support for antibiotic-associated and traveler's diarrhea but not for hospital-acquired infection, and L. rhamnosus GG's benefit was limited to one indication among seven tested.

Who profits, and who pushes back

  • Dr. Mary Ellen Sanders

    Promotes itISAPP probiotics scientist

    Leading academic voice insisting on strain-level specificity and accurate labeling; critic of generic claims.

  • Supplement marketers

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itMass-market probiotics

    Routinely make broad "gut health/immunity" claims using strains with no evidence for those uses, the core problem this principle exposes.

  • Dr. Lynne McFarland

    Promotes itProbiotic meta-analyst

    Authored major strain- and disease-specificity reviews showing effects do not generalize across strains.

  • Lynne V. McFarland

    Pushes backLead author, 228-trial systematic review, Frontiers in Medicine 2018

    The efficacy of probiotics is both strain-specific and disease-specific, and reviews and meta-analyses that pool together different types of probiotics result in misleading conclusions of efficacy.

  • Hill, Guarner, Sanders et al. (ISAPP consensus panel)

    Pushes back2014 consensus statement, Nature Reviews Gastroenterology & Hepatology

    A probiotic must be identified to the strain level, because health benefits are attributed to specific strains and cannot be assumed to be shared by others of the same species unless a common mechanism is demonstrated.

  • Francisco Guarner et al. (WGO)

    Pushes backWorld Gastroenterology Organisation Global Guidelines, 2024

    The effects of probiotics are strain-specific and dose-specific, and recommendations should tie specific strains to the claimed benefits based on human studies.

Where the research comes from

Share of published research by country of origin.
PlaceShare of published research
USA34%
Europe34%
Asia18%
Other14%

Research published from: Global.

How we got here

The principle grew out of the field maturing through the 2000s and 2010s, when probiotic trials proliferated globally and results repeatedly refused to generalize across strains. Much of the foundational strain science traces to work on named lineages from many regions: Lactobacillus rhamnosus GG isolated in the United States, Saccharomyces boulardii drawn by Henri Boulard from lychee and mangosteen fruit in French Indochina (present-day Vietnam), and Bifidobacterium and Lactobacillus strains characterized across European, Japanese, and Latin American programs. Meta-analysts, notably Lynne McFarland, and scientists organized around ISAPP pushed the field toward strain-level reporting. The 2014 Hill consensus fixed the modern definition around identified strains, Binda 2020 set qualifying criteria, and McFarland's 2018 review of 228 trials documented both strain- and disease-specificity. Consumer marketing has lagged this science, still selling broad 'gut health' benefits on unrelated strains.

  1. 2001FAO/WHO working group frames probiotics around defined, identified strains
  2. 2002FAO/WHO guidelines recommend genus, species, and strain designation on labels
  3. 2014Hill et al. ISAPP consensus (Nat Rev Gastroenterol Hepatol) fixes the modern probiotic definition around identified strains
  4. 2018McFarland, Evans, Goldstein review 228 RCTs (1970-2017), confirming strain- and disease-specificity
  5. 2020Binda et al. publish criteria to qualify microorganisms as 'probiotic,' formalizing strain-level identification
  6. 2024WGO Global Guidelines restate effects as strain- and dose-specific and caution against pooling strains in meta-analyses
  7. OngoingConsumer labels still ride on genus/species while evidence lives at the strain level

At a glance

Key principle
Effects are strain + disease specific
Naming
Genus, species, strain (e.g. L. rhamnosus GG)
Implication
Most label claims are unsupported
Best-evidence strains
LGG, S. boulardii CNCM I-745, others

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Strain Specificity. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources